Benzoic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Benzoic acid: Topical antimicrobial/keratolytic agent → bronchitis
One-Sentence Summary
Benzoic acid is marketed in India in topical ointment products. The TxGNN model predicts it may be effective for bronchitis, but this is a model prediction only, with 0 clinical trials and 2 publications, and neither publication studies benzoic acid.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | bronchitis |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data |
| Number of Listed Products | 3 (valid: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for benzoic acid. It is known as a preservative and a metabolic intermediate, and it is marketed in India in single-ingredient ointments.
No credible mechanistic link to bronchitis is established. The high TxGNN score is a model-based output only. The two retrieved papers are a review of repaglinide in type 2 diabetes and a study of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. Neither studies benzoic acid, so they provide no direct support.
The current marketed products are topical ointments, while bronchitis would likely require a different route of administration. Route compatibility has not been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11577798 | 2001 | Review | Drugs | Review of repaglinide, a benzoic acid derivative, in type 2 diabetes. It does not study benzoic acid or bronchitis. |
| 22180869 | 2012 | Preclinical | Am J Respir Cell Mol Biol | A soluble epoxide hydrolase inhibitor was tested in smoke-induced COPD (bronchitis is one component). It does not study benzoic acid. |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 60907 | Dersol BH Ointment | Tube of 30 gm ointment | Not recorded |
| 115674 | Keralin Ointment | Tube of 15 gm ointment | Not recorded |
| 72830 | Exsora Ointment | Tube of 15 gm ointment | Not recorded |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone. No clinical trial or publication studies benzoic acid in bronchitis, so the evidence level is L5. The marketed forms are topical ointments, which do not obviously fit this respiratory condition.
To proceed, the following is needed:
- Mechanism of action data for benzoic acid
- Package insert warnings and contraindications from the licence holders
- Any preclinical or clinical studies that directly test benzoic acid in bronchitis
- An assessment of a suitable route of administration and formulation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.